Isomorphic Labs raises $5bn to put AI-designed drugs into trials
The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and Alphabet taking part. Isomorphic was spun out of DeepMind in 2021 and is run by Demis Hassabis. It raised $2.1 billion in May. The company reports positive preclinical results in oncology and immunology, and has no approved drug yet.
Where this came from. 4 outlets reported this. We read them, then wrote the sixty words above.